Literature DB >> 12765306

Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.

I W Graziadei1, G E Obermoser, N T Sepp, K H Erhart, W Vogel.   

Abstract

Atorvastatin and other members of the statin family are widely used for the treatment of hypercholesterolaemia in order to reduce the risk of atherosclerosis and cardiovascular disease. Atorvastatin-induced adverse events are mostly mild and only a few cases of lupus-like syndrome or severe acute hepatitis have been documented. In this case report we describe a patient who developed an atorvastatin-induced severe autoimmune hepatitis. In addition, this patient presented with a concomitant systemic lupus-like syndrome which has been already described for statins but not in association with severe liver disease. Although the drug was immediately withdrawn the disease persisted and even deteriorated to a fulminant disease with evidence of acute hepatic failure. The patient failed to respond to conventional immunosuppression with corticosteroids and azathioprine. Only the introduction of intense immunosuppressive therapy, as used in solid organ transplantation, led to a complete and sustained recovery of the patient. Interestingly, the patient was HLA DR3- and HLA DR4-positive, which are well-known genetic factors associated with autoimmune diseases. This case is the first report of a drug-induced lupus-likesyndrome concomitant with a severe autoimmune hepatitis in a genetically predisposed patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765306     DOI: 10.1191/0961203303lu313cr

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

1.  Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction.

Authors:  Omar Khokhar; Christopher Gange; Stephen Clement; James Lewis
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

2.  Acute liver injury as initial manifestation of systemic lupus erythematosus-induced myocarditis.

Authors:  Antonia Neonaki; Vassilis Filiopoulos; Maria Bonou; Ioannis Ν Boletis; Evangelos Cholongitas
Journal:  Rheumatol Int       Date:  2021-02-08       Impact factor: 2.631

Review 3.  Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly.

Authors:  Terry A Jacobson
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.

Authors:  Akiko Hisamochi; Masayoshi Kage; Tatsuya Ide; Teruko Arinaga-Hino; Keisuke Amano; Reiichiro Kuwahara; Kei Ogata; Ichiro Miyajima; Ryukichi Kumashiro; Michio Sata; Takuji Torimura
Journal:  J Gastroenterol       Date:  2015-10-30       Impact factor: 7.527

Review 5.  Acute liver failure as the first feature of systemic lupus erythematosus.

Authors:  Mohammad Mustafa; Yasser Mohammed Bawazir
Journal:  Rheumatol Int       Date:  2020-10-09       Impact factor: 2.631

6.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

7.  A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis.

Authors:  Koji Harada; Yasuhiro Akai; Sachi Koyama; Yasuhide Ikenaka; Yoshihiko Saito
Journal:  Clin Rheumatol       Date:  2008-06-18       Impact factor: 2.980

Review 8.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

Review 9.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

10.  Drug-induced liver injury with autoimmune features complicated with hemophagocytic syndrome.

Authors:  Manabu Hayashi; Kazumichi Abe; Hiromichi Imaizumi; Ken Okai; Yukiko Kanno; Atsushi Takahashi; Hiromasa Ohira
Journal:  Clin J Gastroenterol       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.